Bladder cancer
Conditions
Interventions
Resistant/non-susceptible group:None
Susceptible group:None
Sponsors
Fuzhou University Affiliated Provincial Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Aged between 50-70 years old, no gender limit; (2) Locally advanced or metastatic urothelial carcinoma confirmed by histopathology or cytology; (3) Not suitable for receiving cisplatin-based chemotherapy; (4) Receive first-line treatment with RC48 combined with toripalimab; (5) The pre-treatment baseline tissue (FFPE) sample is complete and can be used for RNAseq sequencing analysis; (6) Complete clinicopathological data, including RECIST 1.1 efficacy evaluation results, progression-free survival (PFS), overall survival (OS), HER2 IHC status (IHC 2+/3+) and PD-L1 CPS score.
Exclusion criteria
Exclusion criteria: (1) Age below 50 years or above 70 years old; (2) Pathologically diagnosed non-urothelial cancer, or early-stage urothelial cancer, can be cured radically through surgery and does not require first-line treatment with RC48 combined with toripalimab; (3) Suitable for cisplatin-based chemotherapy regimen; (4) Not receiving first-line treatment with RC48 combined with toripalimab; (5) The baseline tissue (FFPE) sample before treatment is missing or incomplete, and RNAseq sequencing analysis cannot be performed; (6) Clinicopathological data are missing, and RECIST 1.1 efficacy evaluation, PFS/OS statistics, HER2 IHC status or PD-L1 CPS score determination cannot be completed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune cell infiltration analysis;Differentially expressed gene related indicators;Biomarker Identification;Survival related indicators;Functional pathway enrichment analysis; | — |
Countries
China
Contacts
Public ContactLiu Zhihua
Fuzhou University Affiliated Provincial Hospital
Outcome results
None listed